BioNTech Attracts Institutional Backing Ahead of Pivotal Governance Vote

Major investors boost stakes as BioNTech reports strong cancer drug data, plans board overhaul, and navigates strategic pivot with strong cash reserves.

A wave of institutional buying is providing a vote of confidence in BioNTech SE as the company approaches a critical shareholder meeting next month. Fresh 13F filings from April 16 reveal coordinated position-building by major investors. SG Americas Securities LLC dramatically increased its stake, purchasing approximately 345,000 shares to bring its total holding to 365,333, valued at nearly $34.8 million. Lbp Am Sa also raised its position by 4.3 percent, now holding about 369,000 shares worth $35 million. Overall, institutional investors and hedge funds now control 15.52 percent of BioNTech's outstanding shares.

This financial endorsement coincides with significant clinical progress and a planned leadership transition. The company recently reported positive Phase 2 data for its antibody-drug conjugate candidate, BNT323 (trastuzumab pamirtecan), developed with partner DualityBio. In patients with HER2-positive, recurrent endometrial cancer, the confirmed objective response rate was 49.3 percent, with a median progression-free survival of 8.1 months. The asset already holds Fast-Track and Breakthrough Therapy designations from the FDA, and BioNTech aims to submit a regulatory application in 2026, pending further feedback.

The upcoming Annual General Meeting on May 15 will be a defining moment. Shareholders are set to vote on a profound restructuring of the Supervisory Board, expanding it from six to eight members. The proposed new candidates are Dr. Susanne Schaffert and Prof. Dr. Iris Loew-Friedrich, both bringing deep expertise in oncology and clinical development. This governance overhaul is strategically timed, as founders Ugur Sahin and Özlem Türeci are set to depart by the end of 2026 to lead a new independent mRNA research initiative. BioNTech will retain a minority stake and rights to certain technologies from this venture.

Financially, the context remains challenging. The company is scheduled to report quarterly figures on May 6. BioNTech closed 2025 with a net loss of €1.14 billion on revenue of €2.9 billion. Management forecasts a further revenue decline to between €2.0 and €2.3 billion for 2026. Despite this, a liquidity reserve of approximately €17 billion provides substantial runway for its strategic pivot. The AGM agenda also includes requests for new authorized capital for 6, the appointment of EY as auditor, and a domination and profit transfer agreement with subsidiary BioNTech Discovery GmbH, a move that allows for tax consolidation of losses.

The stock, trading at €84.70, has stabilized recently, sitting about 17 percent above its March low and showing a weekly gain of nearly nine percent. Analyst sentiment is broadly positive; among the 18 covering the firm, 13 recommend buying, with a consensus price target of $133. Bank of America recently raised its target to $130, while Morgan Stanley maintains an "Overweight" rating with a $126 target. The company's ambition is clear: it aims to have 15 ongoing Phase 3 studies in oncology by year-end, part of a broader goal to transform into a multi-product company by 2030. The acquisition of CureVac has already been completed. How shareholders vote on May 15 will reveal the depth of market faith in this ambitious transformation.